IsoPSA Assay
Cleveland Diagnostics, Inc. · Decision date Nov 28, 2025
What did the FDA approve?
FDA records P200048 as an original PMA application. The recorded decision is approval, dated Nov 28, 2025.
FDA approval order statement
Approval for the IsoPSA Assay.The IsoPSA Assay is an in vitro test system that combines the results of total Prostate Specific Antigen (PSA) (Elecsys, Roche Diagnostics) and free PSA (Elecsys, Roche Diagnostics) from partitioned heparinized plasma into a single numerical index. The IsoPSA Assay is indicated for use in conjunction with other patient information to aid in detection of high-grade prostate cancer (Grade Group >= 2; Gleason score >= 7) in men >= 50 years of age, with total PSA levels >= 4.0 to =< 10.0 ng/mL for whom a biopsy is being considered by a urologist based on current standard of care, before consideration of IsoPSA Assay results.Prostatic biopsy is required for the diagnosis of cancer.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Immunology
- Decision date
- Nov 28, 2025
Regulatory record facts
- Identifier
- P200048
- Regulatory pathway
- Premarket approval application
- Applicant
- Cleveland Diagnostics, Inc.
- Product code
- QRF
- Decision code
- APPR
- Decision date
- Nov 28, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Multi-analyte test system with algorithmic analysis for detection of prostate cancer.
- Applicant
- Cleveland Diagnostics, Inc.
- Product code
- QRF
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P200048 received
Application receipt date recorded by FDA.
P200048 · FDA decision
APPR
P200048/S001 · Related supplement
IsoPSA Assay
Timeline entries are records held by MedtechLedger for P200048. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P200048
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
IsoPSA AssayP200048/S001 | Cleveland Diagnostics, Inc. | PMA supplement | Jul 28, 2026 | FDA |
Explore the linked device profile
Other records with product code QRF
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
4Kscore TestP190022/S003 | Opko Health, Inc. | PMA supplement | Jul 25, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Cleveland Diagnostics, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 3615 Superior Ave., Suite 4407b, Cleveland, OH, 44114
Sources and methodology
- Original FDA record: P200048
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
